
Bloodlines Series: Mapping the Many Paths of Acute Myeloid Leukemia
A single-cell atlas helped clarify diverse forms of acute myeloid leukemia, with potential implications for improving diagnostic, prognostic, and...
A single-cell atlas helped clarify diverse forms of acute myeloid leukemia, with potential implications for improving diagnostic, prognostic, and...
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
Multiple myeloma can be tricky to treat, but many treatment options exist, and new research is constantly supporting more.
Our annual Experts Forecast offers insights from AACR President-Elect Lillian Siu, John E. Dick, Regina Barzilay, Vinod Balachandran, and...
Amidst an FDA investigation into secondary cancers after CAR T therapy, researchers show the risk is likely minimal.
Researchers examined how the molecular features of Hodgkin lymphomas differ between young and older patients.
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
Researchers at the Blood Cancer Discovery Symposium presented data on multidrug resistance and clinical trial design.
AACR will host the inaugural Blood Cancer Discovery Symposium March 4-6, 2024, featuring experts from all areas of blood...